I class uplc

Manufactured by Waters Corporation

Sourced in United States, Germany

The I-Class UPLC is a high-performance liquid chromatography (HPLC) system designed by Waters Corporation. It utilizes the principles of Ultra Performance Liquid Chromatography (UPLC) to provide rapid and efficient separation of complex mixtures. The I-Class UPLC system is capable of operating at high pressures, enabling the use of smaller particle size columns for enhanced resolution and sensitivity.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

I-class UPLC system (14 citations) I-Class (13 citations) I-Class Acquity UPLC (9 citations) I Class Acquity UPLC system (6 citations) I-class Acquity UPLC chromatography system (3 citations)

17 protocols using i class uplc

Paclitaxel Drug Release Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols

Stored tissue and balloon samples were extracted under vortexing and sonication in 1mL of 0.5% formic acid in methanol four times. Extracted paclitaxel was quantified using a validated LC-MS/MS method on a SCIEX Triple Quad 5500+ LC-MS/MS System with ¹³C⁶ paclitaxel (ChromaDex) as an internal standard. Stored balloon samples were also extracted under sonication in 1ml acidic methanol solution. Drug release was calculated as the difference between nominal load and residual paclitaxel las measured on the balloon extracts by ultra performance liquid chromatography on an I-Class UPLC (Waters, Milford, MA).
Total residual paclitaxel on balloon samples was measured by ultra performance liquid chromatography on an I-Class UPLC (Waters, Milford, MA) and drug release was calculated as the difference between nominal and residual drug loads.

Tzafriri A.R., Muraj B., Garcia-Polite F., Salazar-Martín A.G., Markham P., Zani B., Spognardi A., Albaghdadi M., Alston S, & Edelman E.R. (2020). Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients. Biomaterials, 260, 120337.

+ Open protocol

+ Expand

Quantitative Lipidomic Analysis by UPLC-MS

Check if the same lab product or an alternative is used in the 5 most similar protocols

Extracted lipids were separated on a Waters I class UPLC equipped with a Waters CSH C18 column (length 100 mm, diameter 2.1mm, particle size 1.7 μm) using a gradient starting with 57% solvent A (50% methanol, 50% water) and 43 % solvent B (99% 2-propanol, 1% methanol), both solvents containing 10 mM ammonium formiate, 0.1% formic acid and 5 μM sodium citrate. For details see Table S1. The UPLC was coupled to an ESI-(QqQ)-tandem mass spectrometer (Waters Xevo TQ-S) for compound detection in +ESI MRM mode. De novo synthesized SLs were discriminated from steady state SLs by incorporation of ¹³C₃,¹⁵N₁-stable isotope labeled L-serine leading to an n+3 mass shift of the corresponding molecular ions and a corresponding n+2/n+3 mass shift of the product ions in MRM mode. For details see Table S2. Samples were injected and processed using MassLynx software, whereas mass spectrometric peaks were quantified according to their peak area ratio with respect to the internal standard using TargetLynx software (both v 4.1 SCN 843) both from Waters Corporation (Manchester, UK). Subsequently, quantification of ceramides, hexosylceramides, and sphingomyelins was adjusted to the length of the acyl-chain and dihydro(hexosyl)ceramide quantification was further adjusted by a factor calculated between the intensities external ceramides and dihydroceramidstandards of the same concentration.

Wu J., Ma S., Sandhoff R., Ming Y., Hotz-Wagenblatt A., Timmerman V., Bonello-Palot N., Schlotter-Weigel B., Auer-Grumbach M., Seeman P., Löscher W.N., Reindl M., Weiss F., Mah E., Weisshaar N., Madi A., Mohr K., Schlimbach T., Velasco Cárdenas R.M., Koeppel J., Grünschläger F., Müller L., Baumeister M., Brügger B., Schmitt M., Wabnitz G., Samstag Y, & Cui G. (2019). Loss of Neurological Disease HSAN-I-Associated Gene SPTLC2 Impairs CD8+ T Cell Responses to Infection by Inhibiting T Cell Metabolic Fitness. Immunity, 50(5), 1218-1231.e5.

+ Open protocol

+ Expand

High-Resolution Mass Spectrometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

High Mass resolution analyses were performed using a Xevo G2-S QTOF MS (Waters®, Milford, MA, USA) coupled to an IClass UPLC® (Waters®, Milford, MA, USA) system consisting of a binary pump with degasser, autosampler, thermostated column compartment and diode array detector. The MS was operated with an API-ESI source.
Spectra were acquired in positive mode. The capillary voltage was set to 0.25 kV. The cone voltage was set to 25 V. The source temperature was maintained at 140 °C. Acquisition mass range was m/z 50–1200. Nitrogen was used as the nebulizer gas and argon as collision gas. Standard reversed phase gradients were carried out following the LC conditions detailed below. The standard injection volume was 1 μL.
A Lockmass device with Leucine-Enkephalin as standard substance was used for mass calibration. Data acquisition was performed with MassLynx^TM/OpenLynx^TM 4.1 software (Waters®, Milford, MA, USA).

Diaz E., Adhikary S., Tepper A.W., Riley D., Ortiz-Meoz R., Krosky D., Buyck C., Lamenca C.M., Llaveria J., Fang L., Kalin J.H., Klaren V.N., Fahmy S., Shaffer P.L., Kirkpatrick R., Carbajo R.J., Thomsen M, & Impagliazzo A. (2022). Structure of human spermine oxidase in complex with a highly selective allosteric inhibitor. Communications Biology, 5, 787.

+ Open protocol

+ Expand

N-Glycan Profiling of Recombinant IgG1 Fc

Check if the same lab product or an alternative is used in the 5 most similar protocols

N-glycan analysis of rhIgG1 Fc derived from ALB::hIgG1 Fc chicken was performed by UPLC/MS-MS. Briefly, purified rhIgG1 Fc was incubated with PNGase F for 16 h at 37 °C. Deglycosyated rhIgG1 Fc was precipitated using ethanol and centrifuged at 10,000 g for 10 min. The supernatant containing released N-glycan was transferred to a new tube and dried completely using Speed-Vac concentrator. The dried sample was labelled with procainamide for fluorescence analysis. The labeled N-glycan sample was analyzed and quantified using UPLC/MS-MS. An ACQUITY UPLC BEH Glycan column (1.2 × 150 mm, 1.7 μm; Waters, New Castle, DE) with a fluorescence detector (Waters iClass UPLC) was used for the separation and detection of N-glycans. The LC conditions were as follows: flow rate (0.5 mL/min), column temperature (60 °C), mobile phase buffer A (100 mM ammonium formate, pH 4.5), buffer B (100% acetonitrile), injection volume (8 mL), linear gradient (75–60% B for 46.5 min, 60–0% B for 1.5 min, 0% B for 1 min, 0–75% B for 1 min, and 75% B for 13 min). A high-resolution mass spectrometry, triple-TOF MS (AB SCIEX, Concord, Ontario, Canada), was used for N-glycan identification. The N-glycan distribution was analyzed with Empower (Waters).

Park J.S., Choi H.J., Jung K.M., Lee K.Y., Shim J.H., Park K.J., Kim Y.M, & Han J.Y. (2023). Production of recombinant human IgG1 Fc with beneficial N-glycosylation pattern for anti-inflammatory activity using genome-edited chickens. Communications Biology, 6, 589.

+ Open protocol

+ Expand

Quantification of Salicylates in Aspen Foliage

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two μL of all standard and sample solutions was injected onto the UHPLC [Waters Acquity I‐Class UPLC with a photodiode array detector (PDA) and a 3100 SQ mass spectrometer (MS), Milford, MA, USA] and separated peaks with a Waters Acquity CSH C‐18 column (2.1 × 100 mm, 1.7 μm) at 40°C with a flow rate of 0.5 ml/min, using a gradient of water (solvent A) and acetonitrile (solvent B), both containing 0.1% formic acid. The PDA was configured to scan from 210–400 nm, with 1.2‐nm resolution and a sampling rate of 20 points/s. The MS operating parameters for were as follows: cone potential, 30 V; capillary potential, 2,500 V; extractor potential, 3 V; RF lens potential, 0.1 V; source temperature, 120°C; desolvation temperature, 250°C; desolvation gas flow, 500 L/h; cone gas flow, 10 L/h; infusion rate, 5 μl/min; dwell time, 0.025 s.
Standard curves of methanol solutions, also containing the salicylic acid‐d6 internal standard, of various purified compounds were used to calculate the concentrations in the extracted leaves, which were then normalized by sample dry weight and expressed as mg compound g⁻¹. Commercially available standards of salicin (Sigma‐Aldrich), and salicortin, tremuloidin, and tremulacin were used that had been previously isolated and purified from aspen foliage (Lindroth et al., 1986).

Simon S.J., Keefover‐Ring K., Park Y., Wimp G., Grady J, & DiFazio S.P. (2021). Characterization of Salix nigra floral insect community and activity of three native Andrena bees. Ecology and Evolution, 11(9), 4688-4700.

+ Open protocol

+ Expand

Rapid N-glycan Analysis by LC-MS

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies were denatured by RapiGest™ SF (Waters Inc., #186002123) and tris-(2-carboxyethyl)phosphine (120 min, 95°C). N-acetylglucosamine-linked oligosaccharides were released by enzymatic digestion with Rapid PNGase F (10 min, 55°C) (Waters Inc., #186007990) followed by fluorescence tagging with RapiFluor-MS reagent (Waters Inc., #186007989) in dimethylformamide for 5 min at room temperature (RT). For clean-up of tagged glycans a μElution Plate (HILIC SPE, Waters Inc., #186002780) was used. Labeled N-glycans were analyzed by LC–MS employing a HILIC phase (Acquity UPLC BEH GLYCAN 1.7 μ, 2.1 × 150 mm; Waters Inc., #186004742) with an I-class UPLC (Waters Inc.) coupled to a high resolution QTOF mass spectrometer (Impact HD; Bruker Daltonik). Labeled N-glycans are separated using a gradient from 22% B to 44% B within 82 min (mobile phase A: acetonitrile; mobile phase B: 100 mM ammonium formate in H2O, pH4.4). RapiFluor-MS tagged N-glycans were detected with a fluorescence detector at 265 nm excitation wavelength and 425 nm emission wavelength. Fluorescence signals were employed for glycan quantification. Identification of glycan structures was performed by MS and a series of MS/MS experiments using DataAnalysis Software 4.4 (Bruker Daltonik).

Goletz C., Lischke T., Harnack U., Schiele P., Danielczyk A., Rühmann J, & Goletz S. (2018). Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts. Frontiers in Immunology, 9, 1614.

+ Open protocol

+ Expand

Targeted PFAS Analysis by UPLC-MS/MS

Check if the same lab product or an alternative is used in the 5 most similar protocols

The samples were analyzed using an I-Class UPLC (Waters) connected to a QTrap6500 mass spectrometer (Sciex, Darmstadt, Germany) equipped with an electrospray ionization (ESI) source working in the negative mode. The target PFAS analytes injected in samples of 10 µL were separated by reversed-phase chromatography on a HSS T3 column (2 mm × 150 mm, 1.8 µm, Waters) using a gradient of 2 mM ammonium acetate in water/methanol (95:5, solvent A) and 2 mM ammonium acetate in methanol (solvent B). The gradient applied at a flow rate of 0.3 mL/min was: 0 min (0% B), 10 min (95% B), 11 min (95% B), 11.1 min (0% B), 14 min (0% B).
The temperatures of the sample manager and column oven were set to 8 °C and 35 °C, respectively. The mass spectrometer was operated with the following parameters: curtain gas, 20 psi; collision-activated dissociation (CAD) gas, medium; ion source temperature, 450 °C; ion spray voltage, 5500 V; ion source gas 1, 60 psi; ion source gas 2, 50 psi. PFAA and the isotope-labeled standards were detected by multiple reaction monitoring (MRM). The recorded transitions and the respective detection parameters, especially declustering potentials and collision energies, are summarized in Table S1 of the Supplementary Information. Data acquisition and processing were done with Analyst 1.7.1 software (Sciex).

Mertens H., Noll B., Schwerdtle T., Abraham K, & Monien B.H. (2023). Less is more: a methodological assessment of extraction techniques for per- and polyfluoroalkyl substances (PFAS) analysis in mammalian tissues. Analytical and Bioanalytical Chemistry, 415(24), 5925-5938.

+ Open protocol

+ Expand

UPLC-MS/MS Analysis of Vonoprazan and Metabolite

Check if the same lab product or an alternative is used in the 5 most similar protocols

ACQUITY I-Class UPLC and Waters XEVO TQD MS (Milford, MA, USA) were used for the detection of vonoprazan and M-I with an ACQUITY UPLC BEH C18 chromatographic column (50 × 2.1 mm, 1.7 μm) at 40 °C. The mobile phase consisted of acetonitrile and 0.1% formic acid in water in gradient proportions, as shown in Table 1, with a flow rate of 0.4 mL/min. The injection volume of the sample was 2 μL. The scanning method was multiple reaction monitoring (MRM) with detection in positive ion mode and an ESI + ion source. Other mass spectrometry parameters were as follows: capillary voltage 2.0 kV, ion source temperature 150 °C, dissolvent temperature 500 °C, argon flow rate 0.15 mL/min, cone hole gas flow 50 L/h, solvent gas flow 1000 L/h. The precursor ion and product ion were m/z 346.04→314.97 for vonoprazan, m/z 347.50→205.00 for M-I, and m/z 285.10→193.10 for internal standard (IS), diazepam.

Zhou S., Zhao F.L., Wang S.H., Wang Y.R., Hong Y., Zhou Q., Geng P.W., Luo Q.F., Cai J.P, & Dai D.P. (2023). Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo. Pharmaceutical Biology, 61(1), 356-361.

+ Open protocol

+ Expand

UPLC-MS/MS Quantification of Vonoprazan

Check if the same lab product or an alternative is used in the 5 most similar protocols

ACQUITY I-Class UPLC and Waters XEVO TQD MS (Milford, MA, USA) were used for the detection of vonoprazan and M-I with ACQUITY UPLC BEH C18 column (50 mm×2.1 mm, 1.7 μm) (Milford, MA, USA) at temperature of 40°C. The mobile phase consisted of acetonitrile and 0.1% formic acid in gradient proportion with running time of 3 minutes at flow rate of 0.4 mL/min. The injection volume of sample was 2 μL. The scanning method was multiple reaction monitoring (MRM) with detection in positive ion mode and an ESI+ ion source. Other mass spectrometry parameters were listed as following: capillary voltage 2.0 kV; ion source temperature 150 °C; argon flow rate: 0.15 mL/min. The other conditions of mass spectrometry were referred to Shen.10 (link)

Hong Y., Dai D.P., Cai J.P., Wang S.H., Wang Y.R., Zhao F.L., Zhou S., Zhou Q., Geng P.W., Zhou Y.F., Xu X., Shi J.H, & Luo Q.F. (2022). Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo. Drug Design, Development and Therapy, 16, 1779-1789.

+ Open protocol

+ Expand

Skin Permeability Evaluation via PAMPA

Check if the same lab product or an alternative is used in the 5 most similar protocols

pH measurements were carried out in a Crison 2001 pH meter from Hach Lange Spain, (L’Hospitalet de Llobregat, Spain), using a Crison 5202 combined electrode. The electrode system was calibrated with ordinary aqueous buffers at pH 4.01 and 7.00 (25 °C).
A PAMPA Explorer Permeability Assay instrument from Pion Inc. (Billerica, MA, USA), with a Gut-BoxTM and a TempPlate, was used for the skin-PAMPA permeability measurements. The Gut-BoxTM is used to reduce the unstirred water layer thickness, and the TempPlate is used for temperature control during plate incubation.
To quantify the amount of test compounds in the donor and acceptor compartments, a Waters (Milford, MA, USA) I-Class UPLC with diode array detector and an Acquity UPLC BEH C18 (50 × 2.1 mm, 1.7 μm) column also from Waters were used. Instrument control and data processing was performed through the software Empower 3.

Soriano-Meseguer S., Fuguet E., Port A, & Rosés M. (2023). Evaluation of the Ability of PAMPA Membranes to Emulate Biological Processes through the Abraham Solvation Parameter Model. Membranes, 13(7), 640.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!